Form 4: Aethlon Medical Director Receives Equity Grant

Director Edward G. Broenniman acquired 21,815 shares of Aethlon Medical common stock via restricted stock units.

Summary

• Director Edward G. Broenniman was granted 21,815 restricted stock units (RSUs) on April 17, 2026.
• The grant is valued at $2.29 per share.
• The RSUs vest in four equal quarterly installments starting June 30, 2026, through March 31, 2027.
• Following this transaction, the director's total direct beneficial ownership is 23,454 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Retention of board leadership through a multi-quarter vesting schedule.

Negatives

• Dilutive impact of new equity issuance to existing shareholders.

Risks

• Continued service requirement for vesting creates dependency on director retention.

Future Outlook

The director's equity will vest quarterly over the next year, contingent upon continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the medical device and biotechnology sectors to ensure long-term alignment with shareholder value.

Comparison to Industry Standards

• The use of quarterly vesting schedules for director compensation is consistent with standard governance practices for small-cap medical technology firms.
• The grant size is typical for non-executive director compensation packages in the micro-cap biotech space.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution from new share issuance.
• Director: Increased financial stake in company performance.

Next Steps

• Vesting of the first tranche of RSUs on June 30, 2026.

Key Dates

Keywords

Aethlon Medical, AEMD, Form 4, Insider Trading, Equity Compensation, Director Ownership